34
Participants
Start Date
October 31, 2015
Primary Completion Date
November 30, 2021
Study Completion Date
April 30, 2022
nab-Sirolimus
Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
Memorial Sloan Kettering Cancer Center, New York
Duke University Medical Center - Duke Cancer Center, Durham
University of Michigan, Ann Arbor
Washington University School of Medicine - Siteman Cancer Center, St Louis
University of Texas, MD Anderson Cancer Center, Houston
Sarcoma Oncology Research Center, Santa Monica
Stanford University Medical Center, Palo Alto
University of Washington - Seattle Cancer Care Alliance, Seattle
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Aadi Bioscience, Inc.
INDUSTRY